1. Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending;Dusetzina;JAMA Internal Medicine,2017
2. Trends in Medicare Part D Coverage of Generics with Equivalent Brand-Name Drugs;Dusetzina;American Journal of Managed Care,2021
3. Advancing Legislation on Drug Pricing—Is There a Path Forward?;Dusetzina;New England Journal of Medicine,2019
4. Gottlieb
Scott
, and IppolitoBenedic N.2019. “Estimating the Impact of the Newly Proposed Senate Drug Pricing Legislation on Manufacturers’ Investment Decisions.” American Enterprise Institute, September9. https://www.aei.org/economics/estimating-the-impact-of-the-newly-proposed-senate-drug-pricing-legislation-on-manufacturers-investment-decisions/.
5. Hayes
Matthew
, AlcocerPedro, and YiSara. 2019. “Measuring the Impact of Proposed Changes from the Prescription Drug Pricing Reduction Act of 2019 in the Part D Benefit Design for Key Stakeholders.” Milliman, December. https://healthcostcrisis.org/pdfs/WST01.PDPRA%20Analysis.20191217.pdf.